Elevated CD44 Expression on Tumor EC*
Experiment No. . | Normal . | Tumor . |
---|---|---|
RCCs | 200 | 474 |
1 | ||
2 | 30 | 249 |
3 | 310 | 447 |
4 | 200 | 1,162 |
5 | 172 | 1,187 |
6 | 67 | 180 |
7† | 70 | 556 |
8 | 74 | 287 |
9 | 126 | 301 |
10 | 25 | 14 |
11 | 39 | 78 |
12 | 98 | 273 |
13 | 72 | 31 |
14 (VHL) | 359 | 2,300 |
Ovarium carcinomas | 57‡ | 403 |
15 | ||
16 | 90‡ | 396 |
Experiment No. . | Normal . | Tumor . |
---|---|---|
RCCs | 200 | 474 |
1 | ||
2 | 30 | 249 |
3 | 310 | 447 |
4 | 200 | 1,162 |
5 | 172 | 1,187 |
6 | 67 | 180 |
7† | 70 | 556 |
8 | 74 | 287 |
9 | 126 | 301 |
10 | 25 | 14 |
11 | 39 | 78 |
12 | 98 | 273 |
13 | 72 | 31 |
14 (VHL) | 359 | 2,300 |
Ovarium carcinomas | 57‡ | 403 |
15 | ||
16 | 90‡ | 396 |
Abbreviation: VHL; renal cell carcinoma of a patient with Von Hippel-Lindau syndrome.
Mean CD44 (NKI-P1 antibody) fluorescence intensity not corrected for background (<20) values and counterstained with EN4-PE.
The data of this RCC are also given in Fig 1.
Values of ovarium carcinomas are compared to CD44 expression of normal dermis derived EC.